New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
13:43 EDTOREXOrexigen Therapeutics volatility elevated into PDUFA
Orexigen Therapeutics June call option implied volatility is at 164, July is at 116, October is at 88; compared to its 26-week average of 81 according to Track Data, suggesting large movement into the PDUFA goal date of June 10 for Contrave.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
07:37 EDTOREXOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 21, 2015
14:02 EDTOREXParagraph IV patent challenges submitted to FDA for Orexigen's Contrave
An Abbreviated New Drug Application, or ANDA, has been received by the Office of Generic Drugs containing a "Paragraph IV" patent certification for Contrave, the weight loss drug whose patent is owned by Orexigen Therapeutics, according to an FDA notice. The date on which the first substantially complete generic drug application was submitted to the Agency for Contrave was March 12, according to the posting. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use